Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 5/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.33 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702222 | 1.00 | NOTUM (0.39) | NOTUMMEN1KMT2AP2RX7KCNH2 | |
| SCHEMBL30702184 | 0.79 | NOTUM (0.40) | NOTUMKCNH2SIGMAR1CYP3A4F11 | |
| SCHEMBL18797499 | 0.79 | NOTUM (0.40) | NOTUMKCNH2SIGMAR1CYP3A4F11 | |
| SCHEMBL28964606 | 0.78 | KMT2A (0.38) | MEN1KMT2AKCNH2 | |
| SCHEMBL15060116 | 0.73 | NOTUM (0.45) | NOTUMP2RX7KCNH2SIGMAR1CYP3A4 | |
| SCHEMBL30379474 | 0.73 | NOTUM (0.45) | NOTUMP2RX7KCNH2SIGMAR1CYP3A4 | |
| SCHEMBL20359547 | 0.72 | NOTUM (0.50) | NOTUMP2RX7KCNH2SIGMAR1KCNMA1 | |
| SCHEMBL29479362 | 0.72 | NOTUM (0.50) | NOTUMP2RX7KCNH2SIGMAR1KCNMA1 | |
| SCHEMBL20366864 | 0.70 | NOTUM (0.40) | NOTUMP2RX7KCNH2SIGMAR1KCNMA1 | |
| SCHEMBL18797507 | 0.70 | NOTUM (0.74) | NOTUMKCNH2KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022222960-A1 | FXIA INHIBITOR AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| CN-112028877-B | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| CN-112028877-A | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NOTUM 2289/4885MEN1 2632/4885KMT2A 4384/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NOTUM 2289/4885MEN1 2632/4885KMT2A 4384/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885MEN1 2632/4885KMT2A 4384/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885MEN1 2632/4885KMT2A 4384/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NOTUM 2289/4885MEN1 2632/4885KMT2A 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.